1 g follow-up (median, 6.6 years), 10 patients
died of a cardiac cause, 11 patients underwent transplan
2 One patient in the risperidone group
died of a cause regarded as unrelated to treatment.
3 of C57BL/6J mice, all the reconstituted mice
died of a disease with symptoms similar to ET with a lat
4 learning as his son developed and eventually
died of a fungal infection that occurred during a period
5 nt erectile dysfunction, and a third patient
died of a haemopericardium after receiving two bevacizum
6 (MDBK) cells from lung tissue of alpaca that
died of a severe respiratory infection.
7 A third sibling also
died of a similar presentation, but DNA was unavailable
8 One (2%) patient
died of a stent-related cause.
9 Data on all patients who had
died of AAA during the same time period were obtained fr
10 ne left ventricular ejection fraction</=35%)
died of acute heart failure unrelated to ventricular arr
11 t received serum later in the disease course
died of acute infection.
12 In the myocarditis group, 17% (4 of 23)
died of acute rejection after transplantation.
13 tients in the cetuximab and pemetrexed group
died of adverse events compared with five (2%) of 289 tr
14 p and 25 in the docetaxel plus placebo group
died of adverse events possibly unrelated to disease pro
15 s more pronounced for children whose mothers
died of AIDS or tuberculosis compared to other causes of
16 09 women, of whom 165 died of ALS; women who
died of ALS were older (median age, 66 years; interquart
17 The WHI enrolled 161 809 women, of whom 165
died of ALS; women who died of ALS were older (median ag
18 CSF P-tau levels, compared with patients who
died of Alzheimer disease (AD) and other dementias.
19 The patient
died of an intracerebral hemorrhage 6 months after the a
20 The 62-year-old extended criteria donor
died of an intracranial hemorrhage and had undergone car
21 te cancer from 30 rapid autopsies of men who
died of androgen-independent disease.
22 11.4 y of follow-up, 3504 men and 3032 women
died of any cause in this cohort.
23 members of U.S. military service members who
died of any cause since September 11, 2001 (N=1,732).
24 There were 50,990 individuals who
died of any cause, and 3804 who emigrated and were lost
25 For individuals who
died of any cause, mean YLL was 31.4 years (95% CI 30.5-
26 with wild-type pYV(+) Y. pseudotuberculosis
died of apoptosis after 20 h.
27 we found that the remaining Tak1(-/-) HSPCs
died of apoptosis mediated by the caspase-8-dependent ex
28 ,947 person-years, 238 of 1226 (19.4%) women
died of ASVD-related causes.
29 conditional deletion of Dnmt1 in their Tregs
died of autoimmunity by 3 to 4 weeks of age unless they
30 ich the T2/Onc transposon had been mobilized
died of B-ALL by 3 months of age.
31 Among these mice, half
died of B-cell acute lymphoblastic leukemia, T-cell acut
32 .2%) deaths occurred, among whom 164 (53.2%)
died of breast cancer by December 31, 2005.
33 A total of 517 patients
died of breast cancer following a DCIS diagnosis (mean f
34 SCT, we surveyed 141 parents of children who
died of cancer (response rate, 64%) and their physicians
35 surveyed mothers and fathers of children who
died of cancer and were cared for at Children's Hospital
36 Cohabitees of patients who
died of cancer were less likely to die of any cause (IRR
37 ho died of cerebrovascular accident, 217 who
died of cancer, and 200 cardiovascular disease deaths.
38 of cardiovascular diseases, 433 individuals
died of cancer, and 55 individuals died of respiratory d
39 After she
died of cancer, her physician sister discovered, from th
40 ical care services in adults whose cohabitee
died of cancer.
41 By 2006, 8,362 participants had
died of cancer.
42 llow-up, 44 men developed bone metastases or
died of cancer.
43 Totally, 67 patients
died of cancer.
44 Of these, 58%
died of cardiac and 42% of noncardiac causes.
45 Eventually, AI exposed fish
died of cardiac arrest 4 to 5 days after the start of tr
46 ring treatment, including one individual who
died of cardiac arrest that was possibly treatment-relat
47 Two thousand sixteen survivors
died of cardiac disease.
48 also had a duplication of chromosome 6p and
died of cardiac failure.
49 ts required cardiac transplantation and four
died of cardiac failure.
50 n the control group, all animals secondarily
died of cardiac/respiratory failure (8 of 10) or neurolo
51 Two patients
died of cardiogenic shock after the dissection.
52 One patient
died of cardiomyopathy before transplantation.
53 follow-up period of 5.2 years, 203 patients
died of cardiovascular causes or were hospitalized for h
54 ical follow-up was available for 32 women; 5
died of cardiovascular complications within 1 year of di
55 participants died; of those, 350 individuals
died of cardiovascular diseases, 433 individuals died of
56 rly participant in the monotherapy group who
died of cardiovascular failure 13 days after randomisati
57 fewer comorbid conditions than did those who
died of causes other than SCD.
58 from a subject injected 10 years earlier who
died of causes unrelated to gene transfer.
59 tients on eculizumab, all over 50 years old,
died of causes unrelated to PNH.
60 lant before vCJD onset, from a donor who had
died of causes unrelated to vCJD.
61 No patients
died of CDI after a mean follow-up time of 1.8 years; ho
62 coccal dissemination was increased, and mice
died of central nervous system infection.
63 low-up, 793 subjects died, including 279 who
died of cerebrovascular accident, 217 who died of cancer
64 ning histories of women aged 55-79 years who
died of cervical cancer during 1980-2010 (cases) to thos
65 However, one patient
died of chronic rejection 1 year after having been switc
66 Her sister and a first cousin
died of cirrhosis (ages 19 and 6 years) and another 32-y
67 Patients who
died of CJD had elevated CSF T-tau levels and T-tau to P
68 cts prepared from the brains of patients who
died of CJD.
69 heal disease or comorbidity and subsequently
died of colitis.
70 fter a median of 10.9 years, 71 participants
died of colorectal cancer in the screening group vs 330
71 Among deployed US service members who
died of combat or unintentional injuries and received au
72 ectional study of all US service members who
died of combat or unintentional injuries in support of O
73 g-term complete remission rate of 93.8%; 111
died of concomitant disease and 2 of Barrett's esophagus
74 was 5.8% in these patients, but the majority
died of coronary artery disease (38%) and other causes (
75 first-ever nonfatal myocardial infarction or
died of coronary heart disease during follow-up (median
76 None of the 116 relatives
died of CPVT during a 6.7-year follow-up (range, 1.4-20.
77 %) developed nodal metastases; and 21 (2.1%)
died of CSCC.
78 f 14.9 years, a total of 51 subjects (0.67%)
died of CVD causes and 28 (0.37%) died of IHD.
79 768 person-years of follow-up, 12,492 people
died of CVD.
80 5.3-7.6 y), 801 patients died; 342 of those
died of CVD.
81 Three patients with CSI nonseminoma
died of disease (0.3%).
82 patients demonstrated systemic metastases or
died of disease during a mean follow-up period of 10 mon
83 Five patients (10%)
died of disease during follow-up.
84 rcent of patients died during follow-up: 25%
died of disease, 24% died of other causes.
85 Eight patients
died of disease, all after R2 resection.
86 hese 18 patients (28% [18% of all patients])
died of disease-specific causes.
87 Four patients with ECD
died of disease.
88 evidence of disease (NED), and four patients
died of disease.
89 in the retroperitoneum, of whom two patients
died of disease.
90 tients are in clinical remission and only 8%
died of disease.
91 Four patients
died of disseminated disease and 52 patients were alive
92 patients from 7 ocular oncology centers who
died of dissemination were analyzed.
93 For individuals who
died of drug-related causes, longer jail stays were asso
94 One patient in cohort A
died of drug-related complications of immune-related col
95 e majority of homozygous mutant females also
died of dystocia in a maternal genotype-specific manner.
96 000 person-years [PY]) and 9 patients (0.2%)
died of EAC (0.7/1000 PY) in a mean 2.7 +/- 1.6 years.
97 mor recurrence, and the remaining 5 patients
died of early infections.
98 long-term survival whereas all control mice
died of either metastases or chemotherapy toxicity.
99 Cases were defined as individuals who had
died of esophageal cancer, and controls were residents f
100 m the same area (three per case) who had not
died of esophageal cancer, matched by gender and birth y
101 of this cause, nearly 4-fold the number that
died of esophageal cancer.
102 l animals infected with EBOV-C05 or EBOV-C07
died of EVD, whereas 2 of 3 EBOV-K-infected animals died
103 ith and 4100 patients (76%) without diabetes
died of events of cardiovascular origin.
104 ng the hypothesis that HO-1(-/-) macrophages
died of exposure to heme released on erythrophagocytosis
105 One 23-year-old patient in the placebo group
died of fat embolism, and another patient in the placebo
106 Four percent of patients with AF
died of HCM-related causes (n=11), with annual mortality
107 significantly greater than that of those who
died of heart disease ($175 136), cancer ($173 383), or
108 Antithetically, Pgf(-/-) mice rapidly
died of heart failure within 1 week of pressure overload
109 rth but developed dilated cardiomyopathy and
died of heart failure within 4 weeks.
110 One patient
died of hemorrhage recurrence.
111 Two patients have
died of Hodgkin lymphoma progression.
112 ts (0.67%) died of CVD causes and 28 (0.37%)
died of IHD.
113 Two children
died of illnesses other than malaria and were RDT and BS
114 Three patients
died of infection 12 to 14 months after rituximab infusi
115 on (IFN) receptor (IFNAR) became viremic and
died of infection after a high-dose vaginal ZIKV challen
116 Most patients
died of infection or progressive lymphoproliferation.
117 ificantly less patients with the GG genotype
died of infections (P=0.029).
118 Two patients
died of infections before response assessment.
119 e age 5 years in 2013, 51.8% (3.257 million)
died of infectious causes and 44% (2.761 million) died i
120 ose and distant relatives of individuals who
died of influenza were shown to have a significantly inc
121 d for the relatives of 4,855 individuals who
died of influenza.
122 We aimed to describe children who
died of IPD since PCV introduction in England and Wales.
123 e of the patients experienced metastases nor
died of iris melanoma.
124 One patient on placebo
died of ischaemic heart disease.
125 Equal numbers in each group
died of ischemic heart disease.
126 al: 2,200, 5,807) life-years among those who
died of ischemic heart disease.
127 rom a dromedary camel and from a patient who
died of laboratory-confirmed MERS-CoV infection after cl
128 One untreated patient
died of LE.
129 ty mice that received PD-treated splenocytes
died of lethal GVHD.
130 as postmortem brain tissue from a child that
died of leucine intoxication.
131 hs from unknown causes and a heart recipient
died of leukemia at 10 months.
132 h HCV monoinfection were more likely to have
died of liver cancer (odds ratio [OR] = 9.2), drug-relat
133 oinfected decedents were more likely to have
died of liver cancer (OR = 2.2) and drug-related causes
134 he human immunodeficiency virus (HIV) rarely
died of liver disease.
135 Two individuals
died of liver failure, and one individual was successful
136 Overall, 15 patients
died of liver-related complications and 26 developed hep
137 or one patient with pure (de novo) DLBCL who
died of lung cancer.
138 r patients with fee-for service Medicare who
died of lung or colorectal cancer, earlier hospice enrol
139 , or IFN-gamma receptor-deficient recipients
died of lymphoma, indicating that host IFN-gamma signali
140 Eleven study patients
died of malignancy, including two that had achieved a su
141 We compared 10 patients who
died of malignant melanoma 3.7 years (median, range 0.9-
142 estimate, using model I, that 342,203 women
died of maternal causes in 2008, but that contraceptive
143 132 patients without lymphovascular invasion
died of MCC.
144 tly differentially expressed in patients who
died of MCL in both cohorts.
145 One patient
died of meningitis.
146 In August 2013, a 4-year-old boy
died of meningoencephalitis of unknown etiology in a Lou
147 One patient
died of metachronous cancer after STC.
148 One patient
died of metastatic disease with no evidence of local rec
149 with T3a (eyelid TNM)/T2 (Merkel TNM) tumors
died of metastatic MCC.
150 e diagnosed with metastasis and 12 out of 20
died of metastatic spread.
151 Approximately half of the patients
died of metastatic uveal melanoma (10-year rate, 48.5%;
152 r were obtained at autopsy from patients who
died of metastatic uveal melanoma to the liver.
153 However, 11
died of MLD progression, resulting in similar overall su
154 tients (94%), a patient with liver cirrhosis
died of multiorgan failure secondary to sodium overload.
155 e patient who had a combination of syndromes
died of multiorgan failure.
156 mesenteric ischemia, and the patient rapidly
died of multiple organ failure.
157 Furthermore, patients who
died of myeloma (n = 9) had a significantly higher MTV (
158 ease and in infarction areas of patients who
died of myocardial infarctions of different durations.
159 ce failed to control T. gondii infection and
died of necrotizing TE before day 77.
160 the human mitochondrial disease patient who
died of neonatal hypertrophic cardiomyopathy.
161 al weekly dosing scheme; 2 of these patients
died of neutropenic sepsis complications.
162 o developed HCC, and 27%-70% of patients who
died of non-HCC liver-related deaths would have been ide
163 2-1.51), none were shocked by the ICD, and 2
died of nonarrhythmic causes.
164 homozygous familial hypercholesterolemia but
died of noncardiac complications.
165 he PI arm and 14 in the pPCI arm, of whom 20
died of noncardiac reasons (13 in the PI and 7 in the pP
166 eas those with unintentional injury commonly
died of noninjury causes.
167 Seven patients (12%)
died of nonrelapse causes by day 100.
168 One patient
died of nonrelapse mortality; 1 patient relapsed.
169 Of 1490 deceased patients, 620 (41.6%)
died of ocular melanoma.
170 with a necropsy analysis of worms that have
died of old age.
171 ve with confirmed metastases (n = 9) or have
died of other causes (n = 4).
172 nths; range, 14-59 months), and two patients
died of other causes without recurrence.
173 t subsequent ileal pouch-anal anastomosis, 2
died of other causes, and 3 were lost to follow-up.
174 s (median [range] age, 61 [29-71] years) who
died of other causes.
175 ical ventricular reconstruction had SCD; 311
died of other causes.
176 han patients with undiagnosed HAE-C1-INH who
died of other causes.
177 %) men died of prostate cancer and 257 (49%)
died of other causes.
178 d during follow-up: 25% died of disease, 24%
died of other causes.
179 1.49-2.09) for children who had a parent who
died of other causes.
180 t follow-up (2 to 36 months), three patients
died of other infectious complications, and one patient
181 nd 347 (0.34%) in the no screening group had
died of ovarian cancer.
182 and immunoglobulins, the patient ultimately
died of overwhelming sepsis.
183 espite immunomodulating therapy, the patient
died of overwhelming sepsis.
184 dents who were hospitalized >/= 24 h with or
died of pandemic H1N1 infection.
185 d those with a first-degree relative who had
died of PCa (FHD).
186 ctomy, those with first-degree relatives who
died of PCa did not have an increased likelihood of high
187 ents (75%) had disseminated disease, and 55%
died of penicilliosis.
188 to vaccinated mothers required intubation or
died of pertussis.
189 positive patient with multiple sclerosis who
died of PML after receiving 45 infusions of natalizumab.
190 croscopy of brain biopsies from patients who
died of pneumococcal meningitis, we observe that pneumoc
191 One patient
died of pneumonia 24 weeks after implantation, which was
192 Three patients
died of pneumonitis while in the study.
193 Two patients
died of pre-existing viral infections without having thy
194 One patient with baseline psoriasis
died of presumed immune-related colitis after a 1-week d
195 Only 2 patients, both in the NAFLD group,
died of primary liver cancer.
196 (interquartile range, 16.5-74.5); 2 patients
died of progressive CNS disease and small-cell lung canc
197 During BEP, 15 patients
died of progressive disease or toxicity, including one p
198 One patient
died of progressive multifocal leukoencephalopathy.
199 Results Among 31,790 patients, 7,365
died of prostate cancer and 11,811 died from other cause
200 h a median follow-up of 6.4 y, 218 (42%) men
died of prostate cancer and 257 (49%) died of other caus
201 median of 6.4 y of follow-up, 218 men (42%)
died of prostate cancer and 257 (49%) of other causes.
202 developed metastatic disease, and 1.5% have
died of prostate cancer.
203 erize the lethal cell clone in a patient who
died of prostate cancer.
204 In the preceding generation, the mother
died of pulmonary emphysema and she was blind after the
205 We describe a patient who
died of rabies despite a neuroprotective intervention.
206 related mortality, and 2 additional children
died of rapid MLD progression 1.5 and 8.6 years after HS
207 d at relapse, and all patients in this group
died of rapidly progressive disease postrelapse.
208 st 2010, a Minnesota resident, aged 7 years,
died of rapidly progressive meningoencephalitis after lo
209 up for this study was 3.1 years (48 patients
died of RCC) and Cox analysis failed to demonstrate that
210 p of 6.3 years, 4 of the 12 patients (33.3%)
died of recurrent EOC after a diagnosis of breast cancer
211 The remaining 5 recipients
died of recurrent hemorrhage (n=2), liver failure (n=1),
212 Four patients (5%)
died of refractory HIV+MCD and 80 achieved clinical remi
213 Only 1 patient
died of relapsed MCD (at fifth relapse 9.4 years after i
214 Twelve percent
died of related causes and 10% presented superinfection
215 apillary epithelial cell proliferations, and
died of renal failure by 3 mo of age.
216 cifically in kidney tubular epithelial cells
died of renal failure within weeks of birth.
217 weeks, 6 of 9 CfH-deficient MRL-lpr mice had
died of renal failure, whereas all 11 littermate CfH-suf
218 dividuals died of cancer, and 55 individuals
died of respiratory diseases.
219 Klf5(Delta/Delta) mice
died of respiratory distress immediately after birth.
220 Three of the four patients
died of respiratory failure.
221 were HIV-uninfected; eight untested infants
died of respiratory infection (three), sepsis (two), bur
222 all patients with PAH and 75.7% of those who
died of right heart failure received parenteral prostano
223 One child and 3 adults
died of SCD and 2 adults were resuscitated from ventricu
224 Two patients in group B
died of sepsis after febrile neutropenia.
225 One patient
died of sepsis after receiving eight cycles of therapy.
226 enocytes taken post mortem from patients who
died of sepsis is profoundly suppressed, possibly becaus
227 Two patients given TCH
died of sepsis, and one patient given TH experienced sud
228 91 receiving treatment including doxorubicin
died of sepsis, three (1%) of 292 receiving treatment ex
229 three required emergency transplant, and one
died of sepsis.
230 One patient in the immunosuppression group
died of sepsis.
231 The patient had leukemia and neutropenia and
died of septic shock from KPC-producing E. gergoviae bac
232 nt in the phase 1 and 2 studies: one patient
died of septic shock in the phase 1 study; one patient d
233 a-cells as mice aged, and >50% of these mice
died of severe diabetic symptoms before reaching 1 year
234 esistant to systemic steroids, and 1 patient
died of severe interstitial lung disease.
235 Four children from two unrelated kindreds
died of severe pulmonary disease during infancy followin
236 t no LACDeltahla-infected rabbits (P < .005)
died of severe sepsis with disseminated infection.
237 follow-up without complications and 1 animal
died of shock after the subxiphoid puncture.
238 MNs alone suffered from severe illnesses or
died of similar viral challenges.
239 Extracts from brains of two patients, who
died of sporadic Creutzfeldt-Jakob disease (sCJD), conta
240 roke or cardiovascular disease, 532 patients
died of stroke (cases), and 57,734 remained free of inci
241 One patient with high baseline risk
died of stroke 7 years after implant.
242 he 1.6 million patients >70 years of age who
died of stroke since 2002, donor livers were retrieved f
243 There was 1 sepsis-related death, 1 patient
died of sudden hemoptysis, and 2 patients developed recu
244 resonance imaging in people who subsequently
died of sudden unexpected death in epilepsy.
245 res during video-EEG recording and who later
died of SUDEP.
246 (0.14%) and 1342 nonbereaved persons (0.07%)
died of suicide (IRR = 2.02 [95% CI, 1.75-2.34]); IRR =
247 2.61-4.52) for children who had a parent who
died of suicide, and IRR = 1.76 (95% CI, 1.49-2.09) for
248 In the surgery group, one (4%) patient
died of surgical complications and 12 (44%) patients had
249 One patient in the ECX group
died of suspected treatment-related neutropenic sepsis.
250 all patients with widespread chorioretinitis
died of systemic complications of M. chimaera infection
251 amily history was remarkable for an aunt who
died of systemic lupus erythematosus and for a brother w
252 xillary abscess, of a 17-year-old female who
died of tampon-related toxic shock syndrome.
253 (AGO2), and HEN1 RNA methyltransferase genes
died of TCV infection, whereas the wild-type Col-0 plant
254 on, similar to that observed in patients who
died of the 1918 H1N1 pandemic.
255 y, similar to that observed in patients that
died of the 1918 H1N1 pandemic.
256 italization of an elderly male relative, who
died of the disease.
257 of age, 4 (20%) developed frank leukemia and
died of the disease.
258 Twenty
died of the hemorrhage or associated illnesses, and we o
259 e, fewer mice infected with hla(-) S. aureus
died of the infection, compared with those infected with
260 Two
died of the progression of preexisting heart failure wit
261 163 people as of 10 January 2014; 50 of them
died of the severe respiratory infection caused by these
262 ge, 12-56 months), three patients (5.2%) had
died of their cancer.
263 Four patients (1.6%)
died of their disease during follow-up.
264 were diagnosed with prostate cancer and 395
died of their disease.
265 ollow-up duration of 24 months, 134 patients
died of their disease.
266 Most patients with PAH in our cohort
died of their disease; however, right ventricular failur
267 h measures, babies who would have previously
died of these diseases before they were recognized are n
268 5.6 per 1000 patients); 168 patients with BE
died of this cause, nearly 4-fold the number that died o
269 During follow-up, 1083 study participants
died; of those, 350 individuals died of cardiovascular d
270 One patient
died of thrombosis in the superior mesenteric artery.
271 One patient
died of thrombosis in the superior mesenteric artery.
272 13 (6%) patients
died of toxicity.
273 Six patients
died of transplant complications following a second HSCT
274 One of 24 patients
died of transplantation-related complications.
275 Among the transplanted patients, 4 children
died of transplantation-related mortality, and 2 additio
276 ree patients in the etirinotecan pegol group
died of treatment-related adverse events (pneumonia, mye
277 atients (4%) discontinued treatment, and one
died of treatment-related adverse events.
278 %, 0-2.6) given two delayed intensifications
died of treatment-related causes compared with none in t
279 onset PTLD with the majority of patients who
died of treatment-related causes rather than disease pro
280 No patients
died of treatment-related complications.
281 Two patients in the capecitabine group
died of treatment-related complications; as compared wit
282 Four patients
died of treatment-related toxicity (arm A, n = 1; arm B,
283 About 1.3 million people
died of tuberculosis in 2012, despite availability of ef
284 Seventeen (77.2%) patients
died of tumor recurrence, and the remaining 5 patients d
285 ied within 5 years of surgery, and 235 (39%)
died of tumor recurrence.
286 Otto
died of typhus two years after his younger brother's dea
287 Danish family members, including a child who
died of unknown causes at 14 months of age.
288 ntention to treat, excluding one patient who
died of unrelated causes before first treatment.
289 ing shortly before implantation, and another
died of unrelated causes during the safety period with a
290 trol samples of cerebellum from patients who
died of unrelated diseases were examined.
291 Ten patients
died of unrelated illnesses within 1 year after transpla
292 92 receiving treatment excluding doxorubicin
died of varicella, metabolic seizure, and sepsis during
293 ears), 4630 were admitted to hospital for or
died of venous thromboembolism.
294 which time 6438 were admitted to hospital or
died of VTE.
295 ,480 men in the cohort, a total of 4,952 men
died, of which 1,637 men died from cardiovascular diseas
296 During follow-up, 81 (12%) patients
died, of which 38 (47%) died from cardiovascular causes.
297 hospitalization, 25% (12/48) of patients had
died, of whom only 1 initiated CAS; 67% (8/12) of these
298 e vs after the mandate, while the percentage
died of wounds (4.1% [83 of 2025] vs 4.3% [380 of 8791];
299 nnel who were killed in action and those who
died of wounds at a medical facility.
300 [84 of 278]; P < .01), while the percentage
died of wounds was lower among those critically injured